Je was op zoek naar: ipertermija (Maltees - Engels)

ipertermija
depression

deni/ipertermija
pyrexia/hyperthermia

infjammazzjoni ipertermija deni
inflammation hyperthermia pyrexia

dehxa ta’ bard, ipertermija, denib, edima
chills, hyperthermia, pyrexiab, oedema

ipertermija (3-6 sigħat wara l-injezzjoni)
hyperthermia (3-6 hours after injection)

riskji ewlenin huma marbuta ma' soffokazzjoni u ipertermija.
main risks linked to suffocation and hyperthermia.

komuni ħafna: deni/ipertermija* komuni: uġigħ lokali
very common: pyrexia/hyperthermia* common: local pain*

edema periferali, dehxiet, mard bħal influwenza, tħossok ma tiflaħx, ipertermija
peripheral oedema, chills, influenza-like illness, malaise, hyperthermia

f'każijiet rari ħafna ipertermija li tgħaddi tista’ sseħħ sa jumejn.
in very rare cases transient hyperthermia may occur for up to 2 days.

lanqas ma għandu jintuża fuq klieb li għandhom jew huwa suspettat li għandhom suxxettibbiltà ġenetika għal ipertermija malinna.
neither must it be given to dogs with a known or suspected genetic susceptibility to malignant hyperthermia.

ipertermija ħafifa u temporanja sseħħ b’mod komuni ħafna fil-jum tat-tilqima.
a mild and transient hyperthermia very commonly occurs on the day of vaccination.

kultant jista’ jkun hemm apatija u ipertermija (il -fuq minn 39.5˚c)
transient apathy and hyperthermia (above 39.5 °c) may occur.

il-possibilità li sevoflurane jikkaġuna każi ta’ ipertermija mhix ikkontrollata fi klieb suxxetibli ma għandhiex tiġi eskluża.
the possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.

jistgħu jiġu osservati sinjali temporanji oħrajn li jidhru b’mod komuni wara tilqima bħal ipertermija, apatija u disturbi diġestivi li jdumu minn 1 sa 6 ijiem.
other transient signs seen following vaccination such as hyperthermia, apathy and digestive disorders lasting 1 to 6 days are common.

jistgħu jseħħu wkoll dawn is-sintomi li ġejjin: ipertermija u perspirazzjoni li jikkawżaw deidratazzjoni, irrekwitezza, aċċessjonijiet, alluċinazzjonijiet u ipogliċemija.
the following symptoms can also arise: hyperthermia and perspiration, leading to dehydration, restlessness, convulsions, hallucinations and hypoglycaemia.

f’ każijiet rari jista ’ jkun hemm uġigħ u ipertermija lokali (żieda fit- temperatura tal- ġisem).
pain and local hyperthermia (increase in body temperature) can occur in rare cases.

l-iktar reazzjonijiet avversi tal-użu ta’ nexobrid irrappurtati b’mod komuni huma wġigħ lokali u deni/ipertermija temporanji.
the most commonly reported adverse reactions of the use of nexobrid are local pain and transient pyrexia/hyperthermia.

23 is- sintomi tas- sindrome ta ’ serotonin jistgħu jinkludu tibdil fl- istat mentali (eż., aġitazzjoni, alluċinazzjonijiet, koma), instabilità awtonomika (eż., takikardija, pressjoni tad- demm instabbli, ipertermija), aberrazzjonijiet newromuskolari (eż., iperrefleksja, nuqqas ta ’ koordinazzjoni) u/ jew sintomi gastrointestinali (eż., nawseja, rimettar, dijarea).
serotonin syndrome symptoms may include mental status changes (e. g., agitation, hallucinations, coma), autonomic instability (e. g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e. g., hyperreflexia, incoordination) and/ or gastrointestinal symptoms (e. g., nausea, vomiting, diarrhoea).